Home
Storia in 1 fonti
Pharmalittle: We're reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
A study of Lilly's retatrutide weight loss drug in people with heart disease did not answer a crucial question — whether it reduces cardiovascular risk
Raccontata da
statnews.com
Timeline cronologica
- ·
Pharmalittle: We're reading about Novo suing Lilly over 'deceptive' ads, a fugitive's secret life in biotech, and more
Novo Nordisk sued Eli Lilly for allegedly running “deceptive” ads to make its obesity and diabetes drugs appear more effective
- ·
New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
On secondary endpoints that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk of death, heart attack, or stroke.
- ·
Pharmalittle: We're reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
A study of Lilly's retatrutide weight loss drug in people with heart disease did not answer a crucial question — whether it reduces cardiovascular risk